Keywords
Janus Kinase Inhibitors
Biological Products
How to Cite
Abstract
Atopic Dermatitis (AD) is a chronic inflammatory disease that predominantly affects children and adolescents, with a significant impact on their quality of life and psychosocial well-being. The majority of patients with atopic dermatitis have mild forms and improve with hygiene measures and topical treatments, but 5–20% are moderate or severe, and in these cases, other interventions are required. Until a few years ago, immunosuppressants such as systemic corticosteroids, cyclosporine, azathioprine, mycophenolate mofetil, and methotrexate were the only systemic treatment options available for patients with moderate or severe AD, but presently, other therapeutic options exist for these patients, such as biological drugs or JAK inhibitors, among others. This paper aims at reviewing recent advances in the treatment of AD, specifically focusing on these new biological drugs and JAK inhibitors approved for the treatment of moderate to severe AD in children and adolescents, with special attention to the drugs used and available in Uruguay.
References
Esaki H, Brunner P, Renert Y, Czarnowicki T, Huynh T, Tran G, et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol 2016; 138(6):1639-51. doi: 10.1016/j.jaci.2016.07.013.
Faye O, Flohr C, Kabashima K, Ma L, Paller A, Rapelanoro F, et al. Atopic dermatitis: A global health perspective. J Eur Acad Dermatol Venereol 2024; 38(5):801-11. doi: 10.1111/jdv.19723.
Drucker A, Lam M, Prieto D, Malek R, Ellis A, Yiu Z, et al. Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update. JAMA Dermatol 2024; 160(9):936-44. doi: 10.1001/jamadermatol.2024.2192.
Chu A, Wong M, Rayner D, Guyatt G, Díaz J, Ceccacci R, et al. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol 2023; 152(6):1470-92. doi: 10.1016/j.jaci.2023.08.029.
García C, Cubiró X, Puig L. Inhibidores de JAK: usos en dermatología. Parte 1: generalidades, aplicaciones en vitíligo y en alopecia areata. Actas Dermosifiliogr 2021; 112(3):215-23. doi:10.1016/j.ad.2020.12.003.
Yoon S, Kim K, Shin K, Kim H, Kim B, Kim M, et al. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 2024; 38(1):52-61. doi: 10.1111/jdv.19426.
GBD 2021 Asthma and Allergic Diseases Collaborators. Global, regional, and national burden of asthma and atopic dermatitis, 1990-2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Respir Med 2025; 13(5):425-46. doi: 10.1016/S2213-2600(25)00003-7.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol 2022; 36(9):1409-31. doi: 10.1111/jdv.18345.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemictreatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol 2022; 36(11):1904-26. doi: 10.1111/jdv.18429.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Barbarot S, Bieber T, et al. First update of the living European guideline (EuroGuiDerm) on atopic eczema. J Eur Acad Dermatol Venereol 2023; 37(11):e1283-7. doi: 10.1111/jdv.19269.
Deva M, Netting M, Weidinger J, Brand R, Loh R, Vale S. A systematic review of guidelines for the management of atopic dermatitis in children. World Allergy Organ J 2024; 17(12):100989. doi: 10.1016/j.waojou.2024.100989.
Huang L, Zhao D, Lin H, Zheng H, Li X, Chen L, et al. Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis in adolescents: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2024; 103(38):e39826. doi: 10.1097/MD.0000000000039826.
Silverberg J, Bunick C, Hong H, Mendes P, Stein L, Costanzo A, et al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up). Br J Dermatol 2024; 192(1):36-45. doi: 10.1093/bjd/ljae404.
Paller A, Mendes P, Siegfried E, Eichenfield L, Soong W, Prajapati V, et al. Upadacitinib in adolescents with moderate to severe atopic dermatitis: analysis of 3 phase 3 randomized clinical trials through 76 weeks. JAMA Dermatol 2024; 160(12):1304-13. doi: 10.1001/jamadermatol.2024.3696.
Cork M, Thaçi D, Eichenfield L, Arkwright P, Sun X, Chen Z, et al. Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extDermatol 2021; 184(5):857-70. doi: 10.1111/bjd.19460.
Paller A, Siegfried E, Simpson E, Cork M, Sidbury R, Chen I, et al. Dupilumab safety and efficacy up to 1 year in children aged 6 months to 5 years with atopic dermatitis: results from a phase 3 open-label extension study. Am J Clin Dermatol 2024; 25(4):655-68. doi: 10.1007/s40257-024-00859-y.
Paller A, Flohr C, Cork M, Bewley A, Blauvelt A, Hong H, et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol 2023; 159(6):596-605. doi: 10.1001/jamadermatol.2023.0627.
Reich K, Silverberg J, Papp K, Deleuran M, Katoh N, Strober B, et al. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol 2023; 37(10):2056-66. doi: 10.1111/jdv.19280.
Torrelo A, Rewerska B, Galimberti M, Paller A, Yang C, Prakash A, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol 2023; 189(1):23-32. doi: 10.1093/bjd/ljad096.
Zheng Y, Ding R, Bu J. Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review. Front Immunol 2024; 15:1367099. doi: 10.3389/fimmu.2024.1367099.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 María José González , Patricia Kutscher, Agustina Acosta